Narrowband UVB phototherapy for clinically isolated syndrome: A trial to deliver the benefits of vitamin D and other UVB-induced molecules

Prue H. Hart, Robyn M. Lucas, David R. Booth, William M. Carroll, David Nolan, Judith M. Cole, Anderson P. Jones, Allan G. Kermode

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Low vitamin D and insufficient sun exposure are additive independent risk factors for the development of multiple sclerosis (MS). The usual measure of vitamin D status, serum 25-hydroxy vitamin D [25(OH)D], is also a marker of recent exposure to the UVB rays of sunshine. The main evidence for a protective effect for MS development of higher 25(OH)D comes from observational studies, but this study design cannot separate out whether 25(OH)D is acting as a marker of vitamin D status, sun exposure, or both. In light of a lack of definitive outcomes in MS patients after trials of vitamin D supplementation and the ability of narrowband UVB to induce vitamin D, as well as other immune-regulatory molecules in skin, the Phototherapy for Clinically Isolated Syndrome (PhoCIS) trial was established to investigate the benefits of narrowband UVB, in addition to supplemented vitamin D, on MS development in individuals with Clinically Isolated Syndrome. We propose that the PhoCIS trial provides a fresh approach to re-defining the reported associations of 25(OH)D levels with MS development and progression.

Original languageEnglish
Article number3
JournalFrontiers in Immunology
Volume8
Issue numberJanuary
DOIs
Publication statusPublished - 24 Jan 2017

Fingerprint

Phototherapy
Vitamin D
Multiple Sclerosis
Solar System
Sunlight
Observational Studies
Skin
Serum

Cite this

Hart, Prue H. ; Lucas, Robyn M. ; Booth, David R. ; Carroll, William M. ; Nolan, David ; Cole, Judith M. ; Jones, Anderson P. ; Kermode, Allan G. / Narrowband UVB phototherapy for clinically isolated syndrome : A trial to deliver the benefits of vitamin D and other UVB-induced molecules. In: Frontiers in Immunology. 2017 ; Vol. 8, No. January.
@article{fe4ed66b67834b86b2cfade584fa9b79,
title = "Narrowband UVB phototherapy for clinically isolated syndrome: A trial to deliver the benefits of vitamin D and other UVB-induced molecules",
abstract = "Low vitamin D and insufficient sun exposure are additive independent risk factors for the development of multiple sclerosis (MS). The usual measure of vitamin D status, serum 25-hydroxy vitamin D [25(OH)D], is also a marker of recent exposure to the UVB rays of sunshine. The main evidence for a protective effect for MS development of higher 25(OH)D comes from observational studies, but this study design cannot separate out whether 25(OH)D is acting as a marker of vitamin D status, sun exposure, or both. In light of a lack of definitive outcomes in MS patients after trials of vitamin D supplementation and the ability of narrowband UVB to induce vitamin D, as well as other immune-regulatory molecules in skin, the Phototherapy for Clinically Isolated Syndrome (PhoCIS) trial was established to investigate the benefits of narrowband UVB, in addition to supplemented vitamin D, on MS development in individuals with Clinically Isolated Syndrome. We propose that the PhoCIS trial provides a fresh approach to re-defining the reported associations of 25(OH)D levels with MS development and progression.",
keywords = "Clinically isolated syndrome, Multiple sclerosis, Narrowband UVB phototherapy, Trial, UV-induced immunosuppression, Vitamin D, Vitamin D supplementation",
author = "Hart, {Prue H.} and Lucas, {Robyn M.} and Booth, {David R.} and Carroll, {William M.} and David Nolan and Cole, {Judith M.} and Jones, {Anderson P.} and Kermode, {Allan G.}",
year = "2017",
month = "1",
day = "24",
doi = "10.3389/fimmu.2017.00003",
language = "English",
volume = "8",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media SA",
number = "January",

}

Narrowband UVB phototherapy for clinically isolated syndrome : A trial to deliver the benefits of vitamin D and other UVB-induced molecules. / Hart, Prue H.; Lucas, Robyn M.; Booth, David R.; Carroll, William M.; Nolan, David; Cole, Judith M.; Jones, Anderson P.; Kermode, Allan G.

In: Frontiers in Immunology, Vol. 8, No. January, 3, 24.01.2017.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Narrowband UVB phototherapy for clinically isolated syndrome

T2 - A trial to deliver the benefits of vitamin D and other UVB-induced molecules

AU - Hart, Prue H.

AU - Lucas, Robyn M.

AU - Booth, David R.

AU - Carroll, William M.

AU - Nolan, David

AU - Cole, Judith M.

AU - Jones, Anderson P.

AU - Kermode, Allan G.

PY - 2017/1/24

Y1 - 2017/1/24

N2 - Low vitamin D and insufficient sun exposure are additive independent risk factors for the development of multiple sclerosis (MS). The usual measure of vitamin D status, serum 25-hydroxy vitamin D [25(OH)D], is also a marker of recent exposure to the UVB rays of sunshine. The main evidence for a protective effect for MS development of higher 25(OH)D comes from observational studies, but this study design cannot separate out whether 25(OH)D is acting as a marker of vitamin D status, sun exposure, or both. In light of a lack of definitive outcomes in MS patients after trials of vitamin D supplementation and the ability of narrowband UVB to induce vitamin D, as well as other immune-regulatory molecules in skin, the Phototherapy for Clinically Isolated Syndrome (PhoCIS) trial was established to investigate the benefits of narrowband UVB, in addition to supplemented vitamin D, on MS development in individuals with Clinically Isolated Syndrome. We propose that the PhoCIS trial provides a fresh approach to re-defining the reported associations of 25(OH)D levels with MS development and progression.

AB - Low vitamin D and insufficient sun exposure are additive independent risk factors for the development of multiple sclerosis (MS). The usual measure of vitamin D status, serum 25-hydroxy vitamin D [25(OH)D], is also a marker of recent exposure to the UVB rays of sunshine. The main evidence for a protective effect for MS development of higher 25(OH)D comes from observational studies, but this study design cannot separate out whether 25(OH)D is acting as a marker of vitamin D status, sun exposure, or both. In light of a lack of definitive outcomes in MS patients after trials of vitamin D supplementation and the ability of narrowband UVB to induce vitamin D, as well as other immune-regulatory molecules in skin, the Phototherapy for Clinically Isolated Syndrome (PhoCIS) trial was established to investigate the benefits of narrowband UVB, in addition to supplemented vitamin D, on MS development in individuals with Clinically Isolated Syndrome. We propose that the PhoCIS trial provides a fresh approach to re-defining the reported associations of 25(OH)D levels with MS development and progression.

KW - Clinically isolated syndrome

KW - Multiple sclerosis

KW - Narrowband UVB phototherapy

KW - Trial

KW - UV-induced immunosuppression

KW - Vitamin D

KW - Vitamin D supplementation

UR - http://www.scopus.com/inward/record.url?scp=85012236995&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2017.00003

DO - 10.3389/fimmu.2017.00003

M3 - Article

VL - 8

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - January

M1 - 3

ER -